RedHill Biopharma and Duke Collaborate on Opaganib Development

RedHill Biopharma (RDHL) has released an update.

RedHill Biopharma has announced a collaboration with Duke University School of Medicine to test the drug opaganib as a treatment for phosgene inhalation injury, a potential public safety threat. The partnership aims to advance opaganib development under FDA guidelines, addressing the lack of approved antidotes for this toxic industrial chemical. Opaganib’s broad potential applications and its ongoing evaluation by U.S. government programs highlight its significant role in chemical and pandemic preparedness.

For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.